Strong Financial Performance in 2024
Vericel Corporation reported total revenue exceeding $237 million, marking a 20% growth, alongside a significant profit growth with adjusted EBITDA increasing to over $50 million and GAAP profitability of $10.4 million.
Record Quarterly Financial Results
The fourth quarter of 2024 saw record quarterly revenue of over $75 million, with a gross margin of 78%, adjusted EBITDA margin of 40%, and net income of nearly $20 million.
MACI Franchise Growth
MACI's revenue increased 21% year-over-year in Q4 and 20% for the full year, driven by strong fundamentals, including the highest number of MACI implants and biopsies since launch.
Burn Care Franchise Expansion
Burn Care revenue increased 22% to approximately $40 million for the full year, with underlying demand for Epicel and NexoBrid showing strong growth trends.
Promising MACI Arthro Launch
MACI Arthro's launch indicators are strong, with 250 trained surgeons and significant biopsy growth from trained surgeons, suggesting high market interest.